静脉或骨内注射钙剂与生理盐水对成人院外心脏骤停自主循环恢复的影响:一项随机临床试验
该双盲、安慰剂对照随机临床试验在丹麦中部地区纳入397例成人院外心脏骤停患者,比较最多2次静脉或骨内注射5 mmol氯化钙(n=197)与生理盐水(n=200)的效果,首次剂量在首剂肾上腺素后立即给予。主要终点持续自主循环恢复在钙剂组为19%(37例),生理盐水组为27%(53例),风险比0.72(95%CI 0.49至1.03),风险差-7.6%(95%CI -16%至0.8%),P=0.09。30天生存率钙剂组5.2%(10例) vs 生理盐水组9.1%(18例),风险比0.57(95%CI 0.27至1.18),P=0.17;30天良好神经功能结局(改良Rankin量表评分0-3)钙剂组3.6%(7例) vs 生理盐水组7.6%(15例),风险比0.48(95%CI 0.20至1.12),P=0.12。因担忧钙剂组伤害,试验基于383例的预设中期分析提前终止。
要点
- 在成人院外心脏骤停中,钙剂组持续自主循环恢复19%(37例) vs 生理盐水组27%(53例),风险比0.72(95%CI 0.49至1.03),P=0.09,未达统计学显著。
- 30天生存率钙剂组5.2%(10例) vs 生理盐水组9.1%(18例),风险比0.57(95%CI 0.27至1.18),P=0.17。
- 30天良好神经功能结局(改良Rankin量表评分0-3)钙剂组3.6%(7例) vs 生理盐水组7.6%(15例),风险比0.48(95%CI 0.20至1.12),P=0.12。
- 在测得钙值且自主循环恢复的患者中,高钙血症钙剂组26例(74%) vs 生理盐水组1例(2%)。
- 试验基于383例的预设中期分析,因担忧钙剂组伤害而提前终止;作者结论认为结果不支持在成人院外心脏骤停中使用钙剂。
适用人群与场景
- 成人院外心脏骤停患者,纳入397例随机分组,最终391例纳入分析(钙剂组193例,生理盐水组198例;平均年龄68岁[SD 14],女性114例[29%])。
- 研究在丹麦中部地区进行,时间为2020年1月20日至2021年4月15日,末次90天随访为2021年7月15日。
处置流程与药物剂量
- 干预为最多2次静脉或骨内注射5 mmol氯化钙(n=197)或生理盐水(n=200),首次剂量在首剂肾上腺素后立即给予。
研究设计与关键结果
- 研究类型:双盲、安慰剂对照随机临床试验;样本量397例随机,391例纳入分析(钙剂组193例,生理盐水组198例);无失访。
- 主要终点持续自主循环恢复:钙剂组37例(19%) vs 生理盐水组53例(27%),风险比0.72(95%CI 0.49至1.03),风险差-7.6%(95%CI -16%至0.8%),P=0.09。
- 30天生存:钙剂组10例(5.2%) vs 生理盐水组18例(9.1%),风险比0.57(95%CI 0.27至1.18),风险差-3.9%(95%CI -9.4%至1.3%),P=0.17。
- 30天良好神经功能结局(改良Rankin量表评分0-3):钙剂组7例(3.6%) vs 生理盐水组15例(7.6%),风险比0.48(95%CI 0.20至1.12),风险差-4.0%(95%CI -8.9%至0.7%),P=0.12。
- 在测得钙值且自主循环恢复的患者中,高钙血症钙剂组26例(74%) vs 生理盐水组1例(2%)。
证据类型、等级与局限
- 证据类型:双盲、安慰剂对照随机临床试验。
- 试验基于383例的预设中期分析,因担忧钙剂组伤害而提前终止。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在成人院外心脏骤停中,静脉或骨内注射钙剂相比生理盐水未显著改善持续自主循环恢复,这些结果不支持在成人院外心脏骤停中使用钙剂。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: It is unclear whether administration of calcium has a beneficial effect in patients with cardiac arrest.
OBJECTIVE: To determine whether administration of calcium during out-of-hospital cardiac arrest improves return of spontaneous circulation in adults.
DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial included 397 adult patients with out-of-hospital cardiac arrest and was conducted in the Central Denmark Region between January 20, 2020, and April 15, 2021. The last 90-day follow-up was on July 15, 2021.
INTERVENTIONS: The intervention consisted of up to 2 intravenous or intraosseous doses with 5 mmol of calcium chloride (n = 197) or saline (n = 200). The first dose was administered immediately after the first dose of epinephrine.
MAIN OUTCOMES AND MEASURES: The primary outcome was sustained return of spontaneous circulation. The secondary outcomes included survival and a favorable neurological outcome (modified Rankin Scale score of 0-3) at 30 days and 90 days.
RESULTS: Based on a planned interim analysis of 383 patients, the steering committee stopped the trial early due to concerns about harm in the calcium group. Of 397 adult patients randomized, 391 were included in the analyses (193 in the calcium group and 198 in the saline group; mean age, 68 [SD, 14] years; 114 [29%] were female). There was no loss to follow-up. There were 37 patients (19%) in the calcium group who had sustained return of spontaneous circulation compared with 53 patients (27%) in the saline group (risk ratio, 0.72 [95% CI, 0.49 to 1.03]; risk difference, -7.6% [95% CI, -16% to 0.8%]; P = .09). At 30 days, 10 patients (5.2%) in the calcium group and 18 patients (9.1%) in the saline group were alive (risk ratio, 0.57 [95% CI, 0.27 to 1.18]; risk difference, -3.9% [95% CI, -9.4% to 1.3%]; P = .17). A favorable neurological outcome at 30 days was observed in 7 patients (3.6%) in the calcium group and in 15 patients (7.6%) in the saline group (risk ratio, 0.48 [95% CI, 0.20 to 1.12]; risk difference, -4.0% [95% CI, -8.9% to 0.7%]; P = .12). Among the patients with calcium values measured who had return of spontaneous circulation, 26 (74%) in the calcium group and 1 (2%) in the saline group had hypercalcemia.
CONCLUSIONS AND RELEVANCE: Among adults with out-of-hospital cardiac arrest, treatment with intravenous or intraosseous calcium compared with saline did not significantly improve sustained return of spontaneous circulation. These results do not support the administration of calcium during out-of-hospital cardiac arrest in adults.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04153435.
参考来源
- Vallentin MF, Granfeldt A, Meilandt C, et al. Effect of Intravenous or Intraosseous Calcium vs Saline on Return of Spontaneous Circulation in Adults With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2021. PMID: 34847226. doi:10.1001/jama.2021.20929
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。